Third-line treatment and ¹⁷⁷Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

ABSTRACT:

Aims

There is a controversy as to the relative efficacy of ¹⁷⁷Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether ¹⁷⁷Lu-PSMA RLT and third-line treatment have similar effects and adverse effects (PROSPERO ID CRD42017067743).

Methods

The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in Pubmed and Embase selected articles up to September 2017. A search in ClinicalTrials.gov indicated ongoing studies. The meta-analysis used the random-effects model.

Results

Twelve studies including 669 patients reported ¹

SUBMITTER: von Eyben FE 

PROVIDER: S-EPMC5787223 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature